If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced March 17, the funding will support the advancement of the Thousand Oaks-based company's highly selective Nav1.8 inhibitors currently in clinical development. "This is a…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
